Home » Scientific-Program

Scientific-Program

Keynotes sessions or lectures

  • Immunotherapy in cancer, how does it work? How does it not work? New challenges – Joao Goncalves, Portugal
  • mRNA vaccines in cancer – the next future – Niels Halama, Germany
  • Why and how should we screen for Prostate cancer? Recommendations from the EU Council – Hein Van Poppel, Belgium
  • Breast cancer update – N.N.

Clinical and Practical Sessions

  • Antibody drug conjugate development, where are we?
    Clinical issues, stability, and occupational safety issues
  • Pharmacogenomics 2023 and clinical oncology pharmacists: what do we need to know?
  • Cellular and gene therapy medicine management systems
  • In house production of CAR-T therapy
  • Drug safety and clean working
    Results of the intralaboratory study
  • Pragmatic trials and evolution of clinical trials methodologies in oncology
  • Psycho Oncology: what clinical oncology pharmacists need to know?
  • Prostate cancer: guidelines 2023
  • Innovative drugs in hematology: highlights of 2023
  • Joint session ESOP – SIOP European Society for Pediatric Oncology

Workshops and interactive sessions

  • Management of drug-drug interactions
  • Pharmaceutical consultations, which evolutions?
  • Immunotherapy: an opportunity for clinical pharmacists
    Prevention and management of side effects, interactions with gut microbiota interactions…
  • How to implement Therapeutic Drug Monitoring in Oncology
  • How to work multiprofessionally in cases
  • Supportive care and involvement of clinical oncology pharmacists
  • Herbal medicines and cancer patients’ behaviour: pharmacological and psychological issues
  • Role of clinical oncology pharmacists in tumor boards
  • Progress in medical devices in oncology
  • Joint session ESOP – EONS European Oncology Nursing Society: clinical cases

Debate and Round table discussions

  • New challenges surrounding biosimilars: shortages in biosimilars, iv versus sc discussion…
  • “Derogatory access to new oncology drugs”: regulatory and ethical issues: reaching equal access for all patients? High-cost oncology drugs and proof of added benefit.
  • 2023 EU pharmaceutical package
  • What about adherence of oral anticancer drugs (Session with patient advocate speakers)
  • Burnout and wellbeing in oncology pharmacists

Other topics

  • Activities of the “Young professionals’ group in ECO
  • Oral communications session: selected best abstracts
  • Corner presentations
  • Industry sponsored symposiums
  • ESOP news of the world
  • ESOP research projects and actually updates: QuapoS, EUSOP, outcomes of the SIGs, ESOP certification issues

The program will be updated regularly.